Kantai Bio's first-half net profit fell 9.84% year-on-year to raise 3 billion yuan

, Kantai Bio released its 2019 semi-annual report, reporting revenue of 808 million yuan, net profit of 258 million yuan, net profit of 245 million yuan, down 24.07 percent, 9.84 percent and 10 percent, respectively, from the same period last year.The decline was caused by tighter regulation in the vaccine industry and a high base in the second quarter of last year, the statement said. From the first half of 2019 batch issuance of the overall situation, Kantai Bio a total of 21.4069 million doses of hepatitis B vaccine was issued, for the first half of the domestic batch issue of the largest number of enterprises, accounting for 58.76 percent, and as an important product to drive revenue last year - four seedlings, the first half of the issuance is currently less than one-fifth of last year's full-year batch issuance, According to the data of the China Inspection Institute and Guoyuan Securities Research Report, Kantai Bio only Q2 in the first half of April and June two months there are four seedling batch issuance records, Q1 no batch issuance records, the first half of the four seedling batch issued a total of 90.47 million, compared with the same period last year issued a total of 2.3913 million.Pacific Securities data show that Kantai Bio's first half sales of four seedlings close to 2 million units, revenue of about 550 million yuan, down about 15% from the same period last year, is expected to be the full-year sales of four vaccines in 4.5 million units, contributing to a net profit of about 540 million yuan. In addition, the number of Hib and leprosy vaccines issued decreased to varying degrees year-on-year.It is worth noting that during the reporting period, Kantai Bio initiated the implementation of a non-public stock issue project, which is intended to raise a total of not more than 3 billion yuan for the construction of an international industrial base construction project (phase I) and supplementary working capital for the company's absorption of cell-free living polio and type B haemophilus influenzae vaccine, pneumococcal combination vaccine, leprosy series vaccine and other new vaccine development and industrialization to provide basic protection. Up to now, Kantai Bio has 25 research projects in preclinical research, clinical research or application for drug registration approval.According to Pacific Securities analysis, Kantai bio-research and development of the five seedlings are expected to be listed in 2021-2022; (
Sina Pharmaceutical News
)